Medication adherence: WHO cares?

Mayo Clinic Proceedings

Volumn 86, Issue 4, 2011, Pages 304-314

  Brown, Marie T ^a   Bussell, Jennifer K ^b,c  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c MACNEAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; CARDIOVASCULAR AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOVASCULAR DISEASE; CHRONIC DISEASE; DIABETES MELLITUS; DRUG COST; EMPOWERMENT; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE FINANCING; HEALTH CARE SYSTEM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFORMATION TECHNOLOGY; INTERPERSONAL COMMUNICATION; LONG TERM CARE; MEDICARE; MEDLINE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT DECISION MAKING; PATIENT EDUCATION; PHYSICIAN ATTITUDE; PRESCRIPTION; READING; REVIEW; SOCIOECONOMICS; SYSTEMATIC REVIEW; WORLD HEALTH ORGANIZATION;

EID: 79953297428     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/mcp.2010.0575     Document Type: Review

References (101)

1. Sabaté E, ed. Adherence to Long-Term Therapies: Evidence for Action. Geneva, Switzerland: World Health Organization; 2003.
2. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA. 2006;296(21):2563-2571. (Pubitemid 44903860)
3. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497. (Pubitemid 41127293)
4. Huth EJ, Murray TJ, eds. Medicine in Quotations: Views of Health and Disease Through the Ages. 2nd ed. Philadelphia, PA: American College of Physicians; 2006.
5. Steiner JF, Earnest MA. The language of medication-taking. Ann Intern Med. 2000;132(11):926-930. (Pubitemid 30346866)
6. Winkler A, Teuscher AU, Mueller B, Diem P. Monitoring adherence to prescribed medication in type 2 diabetic patients treated with sulfonylureas. Swiss Med Wkly. 2002;132(27-28):379-385. (Pubitemid 35285222)
7. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903-1913. (Pubitemid 35472129)
8. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113(19):2363-2372.
9. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009;8(5):453-463.
10. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterollowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267- 1278.
11. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2684577/. Published May 19, 2009. Accessed November 12, 2009.
12. Glader EL, Sjölander M, Eriksson M, Lundberg M. Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke. Stroke. 2010;41(2):397-401.
13. Costa FV. Compliance with antihypertensive treatment. Clin Exp Hypertens. 1996;18(3-4):463-472. (Pubitemid 26147311)
14. Cramer JA, Benedict A, Muszbek N, Keskinaslan A, Khan ZM. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract. 2008;62(1):76-87. (Pubitemid 350294021)
15. Elliott WJ. What factors contribute to the inadequate control of elevated blood pressure? J Clin Hypertens (Greenwich). 2008;10(1, suppl 1):20-26.
16. Ho PM, Magid DJ, Shetterly SM, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2008;155(4):772-779. (Pubitemid 351410514)
17. Kettani FZ, Dragomir A, Cote R, et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke. 2009;40(1):213-220.
18. Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120(16):1598-1605.
19. Adams RJ, Albers G, Alberts MJ, et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke. 2008;39(5):1647-1652.
20. Kushner FG, Hand M, Smith SC Jr, et al. 2009 Focused Updates: ACC/AHA Guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on percutaneous coronary intervention (Updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009;120(22):2271-2306.
21. Mann DM, Allegrante JP, Natarajan S, Halm EA, Charlson M. Predictors of adherence to statins for primary prevention. Cardiovasc Drugs Ther. 2007;21(4):311-316. (Pubitemid 47387472)
22. Deambrosis P, Saramin C, Terrazzani G, et al. Evaluation of the prescription and utilization patterns of statins in an Italian local health unit during the period 1994-2003. Eur J Clin Pharmacol. 2007;63(2):197-203.
23. Perreault S, Dragomir A, Blais L, et al. Impact of better adherence to statin agents in the primary prevention of coronary artery disease. Eur J Clin Pharmacol. 2009;65(10):1013-1024.
24. Poluzzi E, Strahinja P, Lanzoni M, et al. Adherence to statin therapy and patients' cardiovascular risk: a pharmacoepidemiological study in Italy. Eur J Clin Pharmacol. 2008;64(4):425-432.
25. Chodick G, Shalev V, Gerber Y, et al. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel. Clin Ther. 2008;30(11):2167-2179.
26. Evans CD, Eurich DT, Lamb DA, et al. Retrospective observational assessment of statin adherence among subjects patronizing different types of community pharmacies in Canada. J Manag Care Pharm. 2009;15(6):476-484.
27. National Cholesterol Education Program (NCEP) Expert Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421.
28. Waters DD, Brotons C, Chiang CW, et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation. 2009;120(1):28-34.
29. Kulkarni SP, Alexander KP, Lytle B, Heiss G, Peterson ED. Longterm adherence with cardiovascular drug regimens. Am Heart J. 2006;151(1):185-191.
30. Newby LK, LaPointe NM, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006;113(2):203-212.
31. Hamann GF, Weimar C, Glahn J, Busse O, Diener HC. Adherence to secondary stroke prevention strategies: results from the German Stroke Data Bank. Cerebrovasc Dis. 2003;15(4):282-288. (Pubitemid 36438733)
32. Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med. 2006;166(17):1842-1847. (Pubitemid 44455166)
33. Melloni C, Alexander KP, Ou FS, et al. Predictors of early discontinuation of evidence-based medicine after acute coronary syndrome. Am J Cardiol. 2009;104(2):175-181.
34. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drugeluting stent placement: results from the PREMIER registry. Circulation. 2006;113(24):2803-2809. (Pubitemid 44305292)
35. Pallares MJ, Powers ER, Zwerner PL, Fowler A, Reeves R, Nappi JM. Barriers to clopidogrel adherence following placement of drug-eluting stents. Ann Pharmacother. 2009;43(2):259-267.
36. Roy P, Bonello L, Torguson R, et al. Temporal relation between clopidogrel cessation and stent thrombosis after drug-eluting stent implantation. Am J Cardiol. 2009;103(6):801-805.
37. Lesaffre E, Kocmanova D, Lemos PA, Disco CM, Serruys PW. A retrospective analysis of the effect of noncompliance on time to first major adverse cardiac event in LIPS. Clin Ther. 2003;25(9):2431-2447. (Pubitemid 37267250)
38. Perreault S, Ellia L, Dragomir A, et al. Effect of statin adherence on cerebrovascular disease in primary prevention. Am J Med. 2009;122(7):647-655.
39. Dragomir A, Côté R, White M, et al. Relationship between adherence level to statins, clinical issues and health-care costs in real-life clinical setting. Value Health. 2010;13(1):87-94.
40. Wiederkehr D, Ogbonnaya A, Casciano R, Makenbaeva D, Mozaffari E, Corbelli J. Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation: analysis in a nationally representative managed-care population. Curr Med Res Opin. 2009;25(9):2327-2334.
41. Biondi-Zoccai GG, Lotrionte M, Agostoni P, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J. 2006;27(22):2667-2674. (Pubitemid 44729867)
42. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA. 2007;297(2):159-168. (Pubitemid 46089732)
43. Airoldi F, Colombo A, Morici N, et al. Incidence and predictors of drugeluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation. 2007;116(7):745-754. (Pubitemid 47255992)
44. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293(17):2126-2130. (Pubitemid 40617065)
45. van Werkum JW, Heestermans AA, Zomer AC, et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol. 2009;53(16):1399-1409.
46. Ryan AA. Medication compliance and older people: a review of the literature. Int J Nurs Stud. 1999;36(2):153-162.
47. Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. JAMA. 2002;288(22):2880-2883. (Pubitemid 35425074)
48. Raynor DK. Medication literacy is a 2-way street [editorial]. Mayo Clin Proc. 2008;83(5):520-522.
49. Kindig D, Affonso D, Chudler E, et al. Health Literacy: a Prescription to End Confusion. Washington, DC: Institute of Medicine of the National Academies; 2004.
50. Baker DW, Parker RM, Williams MV, Clark WS. Health literacy and the risk of hospital admission. J Gen Intern Med. 1998;13(12):791-798.
51. Mancuso CA, Rincon M. Impact of health literacy on longitudinal asthma outcomes. J Gen Intern Med. 2006;21(8):813-817. (Pubitemid 44024925)
52. Brunner R, Dunbar-Jacob J, Leboff MS, et al. Predictors of adherence in the Women's Health Initiative Calcium and Vitamin D Trial. Behav Med. 2009;34(4):145-155.
53. Joyner-Grantham J, Mount DL, McCorkle OD, Simmons DR, Ferrario CM, Cline DM. Self-reported influences of hopelessness, health literacy, life style action, and patient inertia on blood pressure control in a hypertensive emergency department population. Am J Med Sci. 2009;338(5):368-372.
54. Reach G. Is there an impatience genotype leading to non-adherence to long-term therapies? Diabetologia. 2010;53(8):1562-1567.
55. Kripalani S, Henderson LE, Jacobson TA, Vaccarino V. Medication use among inner-city patients after hospital discharge: patient-reported barriers and solutions. Mayo Clin Proc. 2008;83(5):529-535.
56. Molloy GJ, Perkins-Porras L, Bhattacharyya MR, Strike PC, Steptoe A. Practical support predicts medication adherence and attendance at cardiac rehabilitation following acute coronary syndrome. J Psychosom Res. 2008;65(6):581-586.
57. Molloy GJ, Perkins-Porras L, Strike PC, Steptoe A. Social networks and partner stress as predictors of adherence to medication, rehabilitation attendance, and quality of life following acute coronary syndrome. Health Psychol. 2008;27(1):52-58. (Pubitemid 351215347)
58. Kronish IM, Rieckmann N, Halm EA, et al. Persistent depression affects adherence to secondary prevention behaviors after acute coronary syndromes. J Gen Intern Med. 2006;21(11):1178-1183. (Pubitemid 44506872)
59. Sundel KL, Stain-Mahngren R, Andersson A, Aberg-Wistedt A, Schenck-Gustafsson K. High frequency of anxiety and angina pectoris in depressed women with coronary heart disease. Gend Med. 2007;4(2):146-156. (Pubitemid 47245014)
60. Amin AA, Jones AM, Nugent K, Rumsfeld JS, Spertus JA. The prevalence of unrecognized depression in patients with acute coronary syndrome. Am Heart J. 2006;152(5):928-934. (Pubitemid 44642310)
61. Dafer RM, Rao M, Shareef A, Sharma A. Poststroke depression. Top Stroke Rehabil. 2008;15(1):13-21. (Pubitemid 351160087)
62. Frasure-Smith N, Lespérance F. Depression and anxiety as predictors of 2-year cardiac events in patients with stable coronary artery disease. Arch Gen Psychiatry. 2008;65(1):62-71.
63. Jia H, Damush TM, Qin H, et al. The impact of poststroke depression on healthcare use by veterans with acute stroke. Stroke. 2006;37(11):2796-2801. (Pubitemid 44922542)
64. Kripalani S, LeFevre F, Phillips CO, Williams MV, Basaviah P, Baker DW. Deficits in communication and information transfer between hospital-based and primary care physicians: implications for patient safety and continuity of care. JAMA. 2007;297(8):831-841.
65. Winterstein AG, Sauer BC, Hepler CD, Poole C. Preventable drug-related hospital admissions. Ann Pharmacother. 2002;36(7-8):1238-1248. (Pubitemid 34755803)
66. Gordon K, Smith F, Dhillon S. Effective chronic disease management: patients' perspectives on medication-related problems. Patient Educ Couns. 2007;65(3):407-415. (Pubitemid 46241782)
67. Kennedy J, Tuleu I, Mackay K. Unfilled prescriptions of medicare beneficiaries: prevalence, reasons, and types of medicines prescribed. J Manag Care Pharm. 2008;14(6):553-560.
68. Bodenheimer T. Coordinating care: a perilous journey through the health care system. N Engl J Med. 2008;358(10):1064-1071.
69. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;(2):CD000011.
70. Schillinger D, Piette J, Grumbach K, et al. Closing the loop: physician communication with diabetic patients who have low health literacy. Arch Intern Med. 2003;163(1):83-90. (Pubitemid 36091605)
71. Roumie CL, Elasy TA, Greevy R, et al. Improving blood pressure control through provider education, provider alerts, and patient education: a cluster randomized trial. Ann Intern Med. 2006;145(3):165-175. (Pubitemid 46780561)
72. Balamurugan A, Ohsfeldt R, Hughes T, Phillips M. Diabetes self-management education program for Medicaid recipients: a continuous quality improvement process. Diabetes Educ. 2006;32(6):893-900. (Pubitemid 44706816)
73. Praska JL, Kripalani S, Seright AL, Jacobson TA. Identifying and assisting low-literacy patients with medication use: a survey of community pharmacies. Ann Pharmacother. 2005;39(9):1441-1445. (Pubitemid 41197123)
74. US Department of Health and Human Services, Office of Disease Prevention and Health Promotion. America's health literacy: why we need accessible health information. Bethesda, MD: US Dept of Health and Human Services; 2008. http://www.health.gov/communication/literacy/issuebrief/. Accessed November 15, 2010.
75. US Department of Health and Human Services, National Institutes of Health. Clear communication: an NIH health literacy initiative. Bethesda, MD: National Institutes of Health; 2010. http://www.nih.gov/clearcommunication/. Accessed November 15, 2010.
76. Parikh NS, Parker RM, Nurss JR, Baker DW, Williams MV. Shame and health literacy: the unspoken connection. Patient Educ Couns. 1996;27(1):33-39.
77. Perez-Stable EJ, Salazar R. Issues in achieving compliance with antihypertensive treatment in the Latino population. Clin Cornerstone. 2004; 6(3):49-61.
78. Urquhart J. Patient non-compliance with drug regimens: measurement, clinical correlates, economic impact. Eur Heart J. 1996;17(suppl A):8-15. (Pubitemid 26129713)
79. Odegard PS, Capoccia K. Medication taking and diabetes: a systematic review of the literature. Diabetes Educ. 2007;33(6):1014-1029.
80. Chapman RH, Petrilla AA, Benner JS, Schwartz JS, Tang SS. Predictors of adherence to concomitant antihypertensive and lipid-lowering medications in older adults: a retrospective, cohort study. Drugs Aging. 2008;25(10):885-892.
81. Benner JS, Chapman RH, Petrilla AA, Tang SS, Rosenberg N, Schwartz JS. Association between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapy. Am J Health Syst Pharm. 2009;66(16):1471-1477.
82. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713-719. (Pubitemid 47176510)
83. Balu S, Simko RJ, Quimbo RM, Cziraky MJ. Impact of fixed-dose and multi-pill combination dyslipidemia therapies on medication adherence and the economic burden of sub-optimal adherence. Curr Med Res Opin. 2009; 25(11):2765-2775.
84. Hussein MA, Chapman RH, Benner JS, et al. Does a single-pill antihypertensive/lipid-lowering regimen improve adherence in US managed care enrolees? A non-randomized, observational, retrospective study. Am J Cardiovasc Drugs. 2010;10(3):193-202.
85. Schroeder K, Fahey T, Ebrahim S. How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. Arch Intern Med. 2004;164(7):722-732. (Pubitemid 38478694)
86. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8): 1296-1310. (Pubitemid 32804122)
87. Tarn DM, Heritage J, Paterniti DA, Hays RD, Kravitz RL, Wenger NS. Physician communication when prescribing new medications. Arch Intern Med. 2006;166(17):1855-1862. (Pubitemid 44455168)
88. Svensson S, Kjellgren KI, Ahlner J, Säljö R. Reasons for adherence with antihypertensive medication. Int J Cardiol. 2000;76(2-3):157-163.
89. Garner JB. Problems of nonadherence in cardiology and proposals to improve outcomes. Am J Cardiol. 2010;105(10):1495-1501.
90. Miller NH. Motivational interviewing as a prelude to coaching in healthcare settings. J Cardiovasc Nurs. 2010;25(3):247-251.
91. Rubak S, Sandbaek A, Lauritzen T, Christensen B. Motivational interviewing: a systematic review and meta-analysis. Br J Gen Pract. 2005; 55(513):305-312. (Pubitemid 40520908)
92. Ogedegbe G, Chaplin W, Schoenthaler A, et al. A practice-based trial of motivational interviewing and adherence in hypertensive African Americans. Am J Hypertens. 2008;21(10):1137-1143.
93. Abbo ED, Zhang Q, Zelder M, Huang ES. The increasing number of clinical items addressed during the time of adult primary care visits. J Gen Intern Med. 2008;23(12):2058-2065.
94. Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Pub L No. 108-173, 117 Stat 2066.
95. Pellegrino AN, Martin MT, Tilton JJ, Touchette DR. Medication ther- apy management services: definitions and outcomes. Drugs. 2009;69(4): 393-406.
96. Fox D, Ried LD, Klein GE, Myers W, Foli K. A medication therapy management program's impact on low-density lipoprotein cholesterol goal attainment in Medicare Part D patients with diabetes. J Am Pharm Assoc (2003). 2009;49(2):192-199.
97. Planas LG, Crosby KM, Mitchell KD, Farmer KC. Evaluation of a hypertension medication therapy management program in patients with diabetes. J Am Pharm Assoc (2003). 2009;49(2):164-170.
98. Yu AP, Yu YF, Nichol MB, Gwadry-Sridhar F. Delay in filling the initial prescription for a statin: a potential early indicator of medication nonpersistence. Clin Ther. 2008;30(4):761-774, discussion 716.
99. Aronow HD, Novaro GM, Lauer MS, et al. In-hospital initiation of lipid-lowering therapy after coronary intervention as a predictor of longterm utilization: a propensity analysis. Arch Intern Med. 2003;163(21):2576-2582. (Pubitemid 37464415)
100. Fonarow GC. In-hospital initiation of statins: taking advantage of the 'teachable moment' [editorial]. Cleve Clin J Med. 2003;70(6):502, 504-506.
101. Joint Commission on Accreditation of Healthcare Organizations. Using medication reconciliation to prevent errors. Sentinel Event Alert. 2006;(35):1-4.